Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID-19

NCT04315298 is registered in ClinicalTrials.gov with Regeneron Pharmaceuticals as lead sponsor.

NCT NCT04315298
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04315298 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID-19
Lead sponsor
Regeneron Pharmaceuticals
Phase
Phase 2/3
Overall status
Completed
Start date
March 18, 2020
Completion date
September 2, 2020
Enrollment
1,912 (actual)
Sites
62

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19